ImmunoGen,Inc. (NASDAQ:IMGN) Files An 8-K Other Events

ME Staff 8-k
-
0

ImmunoGen,Inc. (NASDAQ:IMGN) Files An 8-K Other Events
ITEM 8.01. OTHER EVENTS

On June21, 2018,ImmunoGen,Inc. (the “Company”) issued a press release announcing that, in connection with its previously announced underwritten public offering, the underwriters have exercised in full their option to purchase an additional 2,055,000 shares of the Company’s common stock at the public offering price of $11.00 per share, less the underwriting discounts. The offering of the option shares is expected to close on or about June25, 2018, subject to the satisfaction of customary closing conditions. The net proceeds to the Company from the offering of the entire 15,755,000 shares, including the option shares, are expected to be approximately $162.6 million after deducting underwriting discounts and estimated expenses associated with the offering. The Company’s press release is filed as Exhibit99.1 to this Current Report on Form8-K and is incorporated herein by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d): The following exhibit is being filed herewith:


IMMUNOGEN INC Exhibit
EX-99.1 2 a18-15671_2ex99d1.htm EX-99.1 Exhibit 99.1     ImmunoGen Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares   Waltham,…
To view the full exhibit click here

About ImmunoGen,Inc. (NASDAQ:IMGN)

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.